These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 34296279)

  • 1. Immortalized striatal precursor neurons from Huntington's disease patient-derived iPS cells as a platform for target identification and screening for experimental therapeutics.
    Akimov SS; Jiang M; Kedaigle AJ; Arbez N; Marque LO; Eddings CR; Ranum PT; Whelan E; Tang A; Wang R; DeVine LR; Talbot CC; Cole RN; Ratovitski T; Davidson BL; Fraenkel E; Ross CA
    Hum Mol Genet; 2021 Nov; 30(24):2469-2487. PubMed ID: 34296279
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Astrocytes generated from patient induced pluripotent stem cells recapitulate features of Huntington's disease patient cells.
    Juopperi TA; Kim WR; Chiang CH; Yu H; Margolis RL; Ross CA; Ming GL; Song H
    Mol Brain; 2012 May; 5():17. PubMed ID: 22613578
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quantitative proteomic analysis of induced pluripotent stem cells derived from a human Huntington's disease patient.
    Chae JI; Kim DW; Lee N; Jeon YJ; Jeon I; Kwon J; Kim J; Soh Y; Lee DS; Seo KS; Choi NJ; Park BC; Kang SH; Ryu J; Oh SH; Shin DA; Lee DR; Do JT; Park IH; Daley GQ; Song J
    Biochem J; 2012 Sep; 446(3):359-71. PubMed ID: 22694310
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Induced pluripotent stem cells from patients with Huntington's disease show CAG-repeat-expansion-associated phenotypes.
    HD iPSC Consortium
    Cell Stem Cell; 2012 Aug; 11(2):264-78. PubMed ID: 22748968
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Progerin-Induced Transcriptional Changes in Huntington's Disease Human Pluripotent Stem Cell-Derived Neurons.
    Cohen-Carmon D; Sorek M; Lerner V; Divya MS; Nissim-Rafinia M; Yarom Y; Meshorer E
    Mol Neurobiol; 2020 Mar; 57(3):1768-1777. PubMed ID: 31834602
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modeling Huntington's disease with induced pluripotent stem cells.
    Kaye JA; Finkbeiner S
    Mol Cell Neurosci; 2013 Sep; 56():50-64. PubMed ID: 23459227
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HD iPSC-derived neural progenitors accumulate in culture and are susceptible to BDNF withdrawal due to glutamate toxicity.
    Mattis VB; Tom C; Akimov S; Saeedian J; Østergaard ME; Southwell AL; Doty CN; Ornelas L; Sahabian A; Lenaeus L; Mandefro B; Sareen D; Arjomand J; Hayden MR; Ross CA; Svendsen CN
    Hum Mol Genet; 2015 Jun; 24(11):3257-71. PubMed ID: 25740845
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genetic correction of Huntington's disease phenotypes in induced pluripotent stem cells.
    An MC; Zhang N; Scott G; Montoro D; Wittkop T; Mooney S; Melov S; Ellerby LM
    Cell Stem Cell; 2012 Aug; 11(2):253-63. PubMed ID: 22748967
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epigenetic and transcriptional modulation of WDR5, a chromatin remodeling protein, in Huntington's disease human induced pluripotent stem cell (hiPSC) model.
    Baronchelli S; La Spada A; Ntai A; Barbieri A; Conforti P; Jotti GS; Redaelli S; Bentivegna A; De Blasio P; Biunno I
    Mol Cell Neurosci; 2017 Jul; 82():46-57. PubMed ID: 28476540
    [TBL] [Abstract][Full Text] [Related]  

  • 10. FOXOs modulate proteasome activity in human-induced pluripotent stem cells of Huntington's disease and their derived neural cells.
    Liu Y; Qiao F; Leiferman PC; Ross A; Schlenker EH; Wang H
    Hum Mol Genet; 2017 Nov; 26(22):4416-4428. PubMed ID: 28973411
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Amelioration of Huntington's disease phenotype in astrocytes derived from iPSC-derived neural progenitor cells of Huntington's disease monkeys.
    Cho IK; Yang B; Forest C; Qian L; Chan AWS
    PLoS One; 2019; 14(3):e0214156. PubMed ID: 30897183
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The first reported generation of several induced pluripotent stem cell lines from homozygous and heterozygous Huntington's disease patients demonstrates mutation related enhanced lysosomal activity.
    Camnasio S; Delli Carri A; Lombardo A; Grad I; Mariotti C; Castucci A; Rozell B; Lo Riso P; Castiglioni V; Zuccato C; Rochon C; Takashima Y; Diaferia G; Biunno I; Gellera C; Jaconi M; Smith A; Hovatta O; Naldini L; Di Donato S; Feki A; Cattaneo E
    Neurobiol Dis; 2012 Apr; 46(1):41-51. PubMed ID: 22405424
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neuronal properties, in vivo effects, and pathology of a Huntington's disease patient-derived induced pluripotent stem cells.
    Jeon I; Lee N; Li JY; Park IH; Park KS; Moon J; Shim SH; Choi C; Chang DJ; Kwon J; Oh SH; Shin DA; Kim HS; Do JT; Lee DR; Kim M; Kang KS; Daley GQ; Brundin P; Song J
    Stem Cells; 2012 Sep; 30(9):2054-62. PubMed ID: 22628015
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Induced pluripotent stem cell lines from Huntington's disease mice undergo neuronal differentiation while showing alterations in the lysosomal pathway.
    Castiglioni V; Onorati M; Rochon C; Cattaneo E
    Neurobiol Dis; 2012 Apr; 46(1):30-40. PubMed ID: 22227000
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recent Overview of the Use of iPSCs Huntington's Disease Modeling and Therapy.
    Csobonyeiova M; Polak S; Danisovic L
    Int J Mol Sci; 2020 Mar; 21(6):. PubMed ID: 32213859
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Manifestation of Huntington's disease pathology in human induced pluripotent stem cell-derived neurons.
    Nekrasov ED; Vigont VA; Klyushnikov SA; Lebedeva OS; Vassina EM; Bogomazova AN; Chestkov IV; Semashko TA; Kiseleva E; Suldina LA; Bobrovsky PA; Zimina OA; Ryazantseva MA; Skopin AY; Illarioshkin SN; Kaznacheyeva EV; Lagarkova MA; Kiselev SL
    Mol Neurodegener; 2016 Apr; 11():27. PubMed ID: 27080129
    [TBL] [Abstract][Full Text] [Related]  

  • 17. iPSC-based drug screening for Huntington's disease.
    Zhang N; Bailus BJ; Ring KL; Ellerby LM
    Brain Res; 2016 May; 1638(Pt A):42-56. PubMed ID: 26428226
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Construction of human 3D striato-nigral assembloids to recapitulate medium spiny neuronal projection defects in Huntington's disease.
    Wu S; Hong Y; Chu C; Gan Y; Li X; Tao M; Wang D; Hu H; Zheng Z; Zhu Q; Han X; Zhu W; Xu M; Dong Y; Liu Y; Guo X
    Proc Natl Acad Sci U S A; 2024 May; 121(22):e2316176121. PubMed ID: 38771878
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reversal of Phenotypic Abnormalities by CRISPR/Cas9-Mediated Gene Correction in Huntington Disease Patient-Derived Induced Pluripotent Stem Cells.
    Xu X; Tay Y; Sim B; Yoon SI; Huang Y; Ooi J; Utami KH; Ziaei A; Ng B; Radulescu C; Low D; Ng AYJ; Loh M; Venkatesh B; Ginhoux F; Augustine GJ; Pouladi MA
    Stem Cell Reports; 2017 Mar; 8(3):619-633. PubMed ID: 28238795
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Human Huntington's Disease iPSC-Derived Cortical Neurons Display Altered Transcriptomics, Morphology, and Maturation.
    Mehta SR; Tom CM; Wang Y; Bresee C; Rushton D; Mathkar PP; Tang J; Mattis VB
    Cell Rep; 2018 Oct; 25(4):1081-1096.e6. PubMed ID: 30355486
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.